Last reviewed · How we verify

NCT03926273

Serum and Urine Ghrelin in Adult Epileptic Patients

Completed Last updated 24 April 2019
What this trial tests

trial in Epilepsy in 80 participants. Completed in 5 February 2019.

Timeline
1 June 2018
Primary endpoint
30 January 2019
5 February 2019

Quick facts

Lead sponsorZagazig University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment80
Start date1 June 2018
Primary completion30 January 2019
Estimated completion5 February 2019
Sites1 location across Egypt

Conditions studied

Sponsor

Zagazig University

Who can join

18 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Several neuropeptides have concerned with epilepsy pathogenesis, ghrelin showed an anticonvulsant effect. There is a potential relation between its level and antiepileptic drugs (AED) response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

Other Zagazig University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03926273.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing